Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3LWUR)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting JNK-interacting protein peptide (pepJIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-N3	DMLHC5V	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Mitogen-activated protein kinase (MAPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GBL-310	DM2IFJQ	Keratosis	ED56	Phase 2	[2]
LTT462	DM94E6W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PF-07799544	DMAO10K	Aggressive cancer	2A00-2F9Z	Phase 1	[4]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[1]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[5]
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-C3	DMSKWBE	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-J6	DMOWULJ	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L	DM5U8WT	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[6]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[6]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[7]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[8]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[6]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-O2	DMTROIQ	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
JNK-interacting protein peptide (pepJIP)	TT3ZIJL	NOUNIPROTAC	Inhibitor	[1]
Mitogen-activated protein kinase (MAPK)	TTVOE6D	NOUNIPROTAC	Inhibitor	[1]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
6	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
8	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.